Daily US Conference Calendar - 30th September 2026: LLY

Medical congress appearances matter differently by issuer type: for large-cap pharma the stock-moving risk is data readouts, trial updates or competitor disclosures presented at the congress rather than the management presentation itself, which historically tends to reiterate existing guidance, while for small-cap single-asset biotechs a conference slot can be the event itself. EASD is the principal diabetes and metabolic disease meeting, and in past cycles Lilly's GLP-1 and incretin franchise has made its congress presence a focus for the whole obesity peer set, where read-across to competitors' pipeline names has often moved the group more than the presenter. The rest of the slate is heavily weighted to small-cap biotech at the Stifel cardiometabolic forum and junior miners at Mining Forum Americas, where conference days of this kind have tended to generate incremental commentary rather than discrete catalysts unless slides or abstracts are released. The relevant tells are any abstracts, posters or slide decks posted alongside the sessions, and whether peers in the same therapeutic areas pre-announce or react. As a schedule item rather than a release, nothing here is itself market-moving; the calendar frames where headlines may originate through the session.